Evaluating the Impact of Mono- and Combination Antihypertensive Therapy with Dihydropyridine and Non-dihydropiridine Calcium Channel Blockers on the Viscoelastic Properties of Arteries and Central Blood Pressure in Patients with Mild to Moderate Hypertens

Yu.M. Sirenko, O.L. Rekovets


Introduction. Nowadays, the search for new methods to reduce cardiovascular risk in the population is widely discussed. Many randomized studies have proven the value of the arterial wall stiffness in worsening prognosis for cardiac patients. Therefore, based on these considerations, therapy that improves the elasticity of the arteries maybe have greater efficacy in preventing major cardiovascular events. Objective of this study — to compare the effectiveness of lerkanidipin and diltiazem combination in different doses among patients with mild to moderate hypertension based on the effect on central blood pressure (CBP) and viscoelastic properties of arteries. Materials and methods. The study involved 123 patients with mild to moderate hypertension, the average office systolic (SBP)/diastolic blood pressure (DBP) — 149.12/91.92 ± ± 1.42/0.93 mmHg. Average age of patients was 51.83 ± 0.86 years. All patients were divided into the groups of therapy. The first group of patients (n = 20) received diltiazem at a dose of 240 mg daily in two steps. The second one (n = 20) — lerkanidipin 20 mg once daily. The third one (n = 22) — non-fixed combination of lerkanidipin 20 mg and diltiazem 240 mg a day. The fourth one (n = 20) — non-fixed combination of lerkanidipin 10 mg and diltiazem240 mg daily. The fifth one (n = 21) — non-fixed combination of lerkanidipin 10 mg and diltiazem 120 mg a day. The sixth one (n = 20) — non-fixed combination of lerkanidipin 20 mg and diltiazem120 mg daily. All patients at the beginning and at end of treatment underwent the following studies: measurement of body weight and height, calculation of body mass index. The diagnosis of overweight or obesity was made according to the World Health Organization criteria (1997). Measurements of office SBP, DBP and heart rate (HR), ambulatory BP monitoring, determination of pulse wave velocity in elastic and muscle arteries, central SBP, biochemical blood assay which included determination of total cholesterol, triglycerides, high-, low- and very low-density lipoprotein cholesterol, atherogenic index were carried out. Duration of treatment was 1 month. Results. After analyzing all the data, it was found that parameters of office SBP and DBP decreased significantly in patients with both mild and moderate hypertension in all groups almost equally. CBP in all treatment groups decreased effectively and equally. In the group of 240 mg diltiazem, CBP significantly decreased by 10.95 mmHg, in group of lercanidipin 20 mg — by 12.18 mmHg, in the group of lercanidipin 20 mg and diltiazem 240 mg combination — by 14.13 mmHg, in the group of combination of lercanidipin 10 mg and diltiazem 240 mg — by 11.93 mmHg, in the group of lercanidipin 10 mg and diltiazem 120 mg combination — by 13.11 mmHg, in the group of combination of lercanidipin 20 mg and diltiazem 120 mg — by 14.82 mmHg. That is, all selected treatment regimens were equally effective in reducing CBP. There was no negative impact of all treatments on the level of blood lipids. Central SBP is associated with DBP level during daily monitoring and with the indicators of the viscoelastic properties of arteries, the level of cholesterol, intima-media thickness of the carotid arteries. In different treatment groups we observed various factors that significantly correlated with the end CBP and the degree of its decline. In the combination therapy group, final CBP was associated with the level of end office SBP, office DBP, indicators of the viscoelastic properties of arteries. In the group of monotherapy, final central SBP was significantly inversely associated with the degree of reduction during the treatment of office HR and office SBP level at the end of treatment. The degree of СBP reduction in combination therapy group was significantly associated with indicators of viscoelastic properties of arteries, as well as with intima-media thickness of the carotid arteries and the level of total cholesterol. All treatment regimens did not significantly affect the average values of indicators of the viscoelastic properties of the arteries (due to short-term observation). Conclusion. Monotherapy and combination of lercanidipin and diltiazem were effective in reducing both office BP and BP with daily monitoring and CBP. In connection with the best tolerability of lercanidipin 20 mg daily and low-dose combination of lercanidipin10 mg and diltiazem 120 mg, these treatment strategies can be recommended for future treatment of patients with mild to moderate arterial hypertension.


hypertension; lercanidipin; diltiazem; central aortic pressure; pulse wave velocity


Радченко Г.Д., Міхєєва К.В., Сіренко Ю.М., Кушнір С.М., Пономарьова Г.В. Ефективність лікування на основі препарату Лоріста-НД — лозартан 100 мг + гідрохлортіазид 25 мг — порівняно з комбінацією бісопролол 10 мг + гідрохлортіазид 25 мг у пацієнтів з помірною та тяжкою артеріальною гіпертензією: дослідження ЕЛІЗА (результати 6-місячного спостереження) // Артеріальна гіпертензія. — 2010. — № 6. — С. 23-35.

Хвороби системи кровообігу як медико-соціальна і суспільно-політична проблема. Аналітично-статистич. посібн. / За ред. В.М. Коваленка, В.М. Корнацького. — К., 2014. — 115 с.

2007 European Society of Hypertension — European Society of Cardiology guidelines for management of arterial hypertension // J. Hypertension. — 2007. — Vol. 25. — P. 1105-1187.

Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications // Am. J. Cardiovasc. Drugs. — 2001. — Vol. 1(5). — P. 387-397.

Barrios V., Navarro A., Esteras A. at al. Investigators of ELYPSE Study. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study // Blood Press. — 2002. — Vol. 11(2). — P. 95-100.

Blacher J., Asmar R., Djane S., London G.M., Safar M.E. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients // Hypertension. — 1999. — Vol. 33. — P. 1111-1117.

Blacher J., Guerin A.P., Pannier B. et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease // Hypertension. — 2001. — Vol. 38. — P. 938-942.

Blacher J., Pannier B., Guerin A.P. et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease // Hypertension. — 1998. — Vol. 32. — P. 570-574.

Boutouyrie P., Achouba A., Trunet P. et al. for the EXPLOR Trialist Group. Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Ate-nolol Combination The EXPLOR Study // Hypertension. — 2010. — Vol. 55. — P. 1314-1322.

Cohn J. Is it the blood pressure or the blood vessel? // Journal of American Society of Hypertension. — 2007. — Vol. 1. — P. 5-16.

Dahlof B., Devereux R.B., Kjeldsen S.E. et al. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

De Ciuceis C., Salvetti M., Rossini C. at al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension // J. Hypertens. — 2014. — Vol. 32(3). — P. 565-574.

Fumiharu Togo and Masaya Takahashi. Heart Rate Variability in Occupational Health — A Systematic Review // Industrial Health. — 2009. — Vol. 47. — P. 589-602.

Horwitz L.D., Weinberger H.D., Clegg L. Comparison of amlodipine and long-acting diltiazem in the treatment of mild or mo-derate hypertension // Am. J. Hypertens. — 1997. — Vol. 10(11). — P. 1263-1269.

Hulley S.B., Furberg C.D., Gurland B., McDonald R., Perry H.M., Schnaper H.W., Schoenberger J.A., Smith W.M., Vogt T.M. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone // Am. J. Cardiol. — 1985. —

Vol. 56(15). — P. 913-920.

Kawano Y., Makino Y., Okuda N., Takishita S., Omae T. Effects of diltiazem retard on ambulatory blood pressure and heart rate variability in patients with essential hypertension // Blood Press. Monit. — 2000 — Vol. 5(3). — P. 181-185.

Li L.X., Tang W., Chen B.J., Wang T. Cross-sectional study of relation between blood pressure and heart rate variability in patients with peritoneal dialysis // Beijing Da Xue Xue Bao. — 2011. — Vol. 43(6). — P. 849-854.

Lindsay R.S., Resnick H.E., Zhu J., Tun M.L., Howard B.V., Zhang Y., Yeh J., Best L.G. Adiponectin and coronary heart disease: the Strong Heart Study // Arterioscler. Thromb. Vasc. Biol. — 2005. — Vol. 25(3). — P. 15-16.

Luk J.H., Walsh B., Yasbin P. Safety and efficacy of prehospital diltiazem // West J. Emerg. Med. — 2013. — Vol. 14(3). — P. 296-300.

Mackenzie I.S., McEniery C.M., Dhakam Z., Brown M.J., Cockcroft J.R., Wilkinson I.B.Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension // Hypertension. — 2009. — Vol. 54(2). — P. 409-413.

Matsui Y., Eguchi K., O’Rourke M. Et al. Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients // Hypertension. — 2009. — Vol. 54. — P. 716-723.

Nayler W.G. Review of preclinical data of calcium channel blockers and atherosclerosis // J. Cardiovasc. Pharmacol. — 1999. — Vol. 2. — P. 7-11.

Paoletti R., Bernini F., Corsini A., Soma M.R. The antiatherosclerotic effects of calcium antagonists // J. Cardiovasc. Pharmacol. — 1995. — Vol. 3. — P. 6-10.

Piccirillo G., Fimognari F.L., Munizzi M.R., Bucca C., Cacciafesta M., Marigliano V. Age-depended influence on heart rate variability in salt-sensitive hypertensive subjects // J. Am. Geriatr. Soc. — 1996. — Vol. 44(5). — P. 530-538.

Protogerou A., Blacher J., Stergiou G.S., Achimastos A., Safar M.E. Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study // J. Am. Coll. Cardiol. — 2009. — Vol. 53(5). — P. 445-451.

Raicu M., Pojoga L., Simionescu N., Simionescu M. Differential effect of two calcium channel blockers nifedipine and diltiazem on atherogenesis in hypercholesterolemic hamster // J. Submicrosc. Cytol. Pathol. — 1996. — Vol. 28(2). — P. 265-275.

Raicu M., Pojoga L., Simionescu N., Simionescu M. The effect of ACE inhibitors on atheroma formation is potentiated by association with a calcium channel blocker. A biochemical and ultrastructural study // J. Submicrosc. Cytol. Pathol. — 1997. — Vol. 29(3). — P. 317-328.

Richard S. Vascular effects of calcium channel antagonists: new evidence // Drugs. — 2005. — Vol. 65(2). — P. 1-10.

Safar M., Protogerou A., Blacher J. Central blood pressure under angiotensin and calcium channel blockade // Hypertension. — 2009. — Vol. 54. — P. 704-706.

Sakurai-Yamashita Y., Harada N., Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP // Cell. Mol. Neurobiol. — 2011. — Vol. 31(4). — P. 561-567.

Salo T.M., Viikari J.S., Antila K.J., Voipio-Pulkki L.M., Jalonen J.O., Valimaki I.A. Antihypertensive treatment and hert rate variability in diabetic patients: role of cardiac autonomic neuropathy // J. Auton. Nerv. Syst. — 1996, Aug 27. — Vol. 60(1–2). — P. 61-70.

Scholze J.E.Differential therapy with calcium antagonists // Herz. — 2003. — Vol. 28(8). — P. 754-763.

Sutton-Tyrrell K., Mackey R.H., Holubkov R. еt al. Measurement variation of aortic pulse wave velocity in the elderly // Am. J. Hypertens. — 2001. — Vol. 14. — P. 463-468.

Wang H.B., Shi Q., Zhang C. Effects of heart rate variabi-lity and smoothness index on reversal of hypertensive left ventricular hypertrophy // Zhonghua Yi Xue Za Zhi. — 2011. — Vol. 91(12). — P. 832-835.

Williams B., Lacy P., Cruickshank J. et al. Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics Principal Results of the Conduit Artery Function Williams B., Lacy P., Cruickshank J. et al. Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics Principal Results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study // Circulation. — 2009. — Vol. 119. — P. 53-61.

Woźnicka-Leśkiewicz L., Posadzy-Małaczyńska A., Jusz-kat R. The impact of ankle brachial index and pulse wave velocity on cardiovascular risk according to SCORE and Framingham scales and sex differences // J. Hum. Hypertens. — 2014. — 25. — doi: 10.1038/jhh.2014.80.

Wright J.T. Jr, Sica D.A., Gana T.J., Bohannon K., Pascual L.G., Albert K.S. Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans // Am. J. Hypertens. — 2004. — Vol. 17(9). — P. 734-742.

Zanchetti A., Bond M.G., Hennig M. at al. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial // Circulation. — 2002. — Vol. 106(19). — P. 2422-2427.

DOI: https://doi.org/10.22141/2224-1485.3.41.2015.80662


  • There are currently no refbacks.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2017


 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru